Mostrar el registro sencillo del ítem
dc.contributor.author | Puñet-Ortiz, Joan | |
dc.contributor.author | Sáez Moya, Manuel | |
dc.contributor.author | Cuenca, Marta | |
dc.contributor.author | Caleiras, E | |
dc.contributor.author | Lazaro, Adriana | |
dc.contributor.author | Engel, Pablo | |
dc.date.accessioned | 2019-09-17T06:17:44Z | |
dc.date.available | 2019-09-17T06:17:44Z | |
dc.date.issued | 2018-11-16 | |
dc.identifier.citation | Front Immunol. 2018;9:2661. | es_ES |
dc.identifier.issn | 1664-3224 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/8354 | |
dc.description.abstract | Sjögren's Syndrome (SjS) is a common chronic autoimmune disease characterized by the B cell hyperactivation, lymphocyte infiltration, and tissue damage of exocrine glands. It can also present life-threatening extraglandular manifestations, such as pulmonary and hepatic involvement, renal inflammation and marginal zone (MZ) B cell lymphoma. Several biologic agents have been tested in SjS but none has shown significant efficacy. Here, we report the effects of Ly9 (CD229) antibody targeting, a cell surface molecule that belongs to the SLAM family of immunomodulatory receptors, using NOD.H-2h4 mice as a model of SjS-like disease. Female mice were treated with anti-Ly9 antibody or isotype control at week 24, when all mice present SjS related autoantibodies, salivary gland infiltrates, and marginal zone (MZ) B cell pool enlargement. Antibody injection depleted key lymphocyte subsets involved in SjS pathology such as MZ, B1, and germinal center B cells in spleen and draining lymph nodes without inducing a general immunosuppression. Importantly, mice receiving anti-Ly9 mAb showed a reduced lymphocyte infiltrate within salivary glands. This reduction may be, in part, explained by the down-regulation of L-selectin and alfa4/beta7 integrin induced by the anti-Ly9 antibody. Furthermore, levels of anti-nuclear autoantibodies were reduced after anti-Ly9 treatment. These data indicate that Ly9 is a potential therapeutic target for the treatment of SjS. | es_ES |
dc.description.sponsorship | The authors thank the NIH tetramer Core Facility for provision of PBS-57-loaded mCD1d tetramers. This work was supported by the Ministerio de Economia y Competividad through Grant SAF2015-69829-R (to PE). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Frontiers Media | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.subject | Ly9 | es_ES |
dc.subject | SLAM family receptors | es_ES |
dc.subject | Sjögren's Syndrome | es_ES |
dc.subject | Antibody targeting | es_ES |
dc.subject | Autoimmunity | es_ES |
dc.title | Ly9 (CD229) Antibody Targeting Depletes Marginal Zone and Germinal Center B Cells in Lymphoid Tissues and Reduces Salivary Gland Inflammation in a Mouse Model of Sjögren's Syndrome | es_ES |
dc.type | journal article | es_ES |
dc.identifier.pubmedID | 30519241 | es_ES |
dc.format.volume | 9 | es_ES |
dc.format.page | 2661 | es_ES |
dc.identifier.doi | 10.3389/fimmu.2018.02661 | es_ES |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1664-3224 | es_ES |
dc.relation.publisherversion | https://doi.org/ 10.3389/fimmu.2018.02661. | es_ES |
dc.identifier.journal | Frontiers in immunology | es_ES |
dc.repisalud.institucion | CNIO | es_ES |
dc.repisalud.orgCNIO | CNIO::Unidades técnicas::Unidad de Histopatología | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/SAF2015-69829-R | es_ES |
dc.rights.accessRights | open access | es_ES |